Breathe Well Live Well
|
MediciNova to Receive $2.5 Million Payment From Kissei Pharmaceutical Co. Ltd …
MarketWatch (press release) Ltd., a pharmaceutical company traded on the Tokyo Stock Exchange (4547), will pay MediciNova $2.5 million, within 30 days, to support further clinical development of MN-221 for the treatment of acute exacerbations of asthma or chronic obstructive … |
View full post on asthma – Google News
|
MediciNova Closes $7.5 Million Private Stock Sale to Kissei Pharmaceutical Co …
MarketWatch (press release) MediciNova's pipeline includes six clinical-stage compounds for the treatment of acute exacerbations of asthma, chronic obstructive pulmonary disease exacerbations, multiple sclerosis and other neurologic conditions, asthma, interstitial cystitis, … |
View full post on asthma – Google News
|
MediciNova, Zhejiang Announce Execution Of China JV To Develop Astma Drug
RTT News (RTTNews) – MediciNova Inc. (MNOV: News ) and Zhejiang Medicine Co., Ltd. Wednesday announced the execution of an agreement for the formation of a Joint Venture to develop and commercialize MediciNova's asthma drug MN-221 in China. … Chinese Joint Venture Completed |
View full post on asthma – Google News
|
MediciNova Reports Fourth Quarter and Full Year 2010 Results
TradersHuddle.com The decrease in research and development expenses primarily related to the completion of the clinical trial evaluating MN-221 at planned escalating doses in patients with severe acute exacerbations of asthma treated in emergency departments in 2009 and … |
View full post on asthma – Google News
|
MediciNova Reports Third Quarter 2010 Results
MarketWatch (press release) The presentations are related to MediciNova's development of MN-221 for potential utility in acute exacerbations of asthma or chronic obstructive pulmonary … |
View full post on asthma – Google News
|
MediciNova (Nasdaq: MNOV) Targets Multi-Billion Dollar Acute Asthma and CNS …
BiotechStockTrader.com (blog) In particular, the company is targeting the multi-billion dollar acute asthma and central nervous system markets. With more than two million patients per … |
View full post on asthma – Google News
|
MediciNova to Present at the Rodman and Renshaw Annual Global Investment …
MarketWatch (press release) MediciNova's pipeline includes six clinical-stage compounds for the treatment of acute exacerbations of asthma, COPD exacerbations, multiple sclerosis and … |
View full post on asthma – Google News
|
MediciNova Reports Second Quarter 2010 Results
MarketWatch (press release) MediciNova's pipeline includes six clinical-stage compounds for the treatment of acute exacerbations of asthma, COPD exacerbations, multiple sclerosis and … |
View full post on asthma – Google News